EAM Global Investors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

EAM Global Investors’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-9,186	Closed	-$716K	–	155
2019 Q3	$716K	Sell	9,186 -15,795	-63%	-$1.48M	0.35%	111
2019 Q2	$2.57M	Sell	24,981 -4,010	-14%	-$312K	1.09%	17
2019 Q1	$2.13M	Buy	+28,991	New	+$1.97M	0.94%	26
2018 Q4	–	Sell	-24,260	Closed	-$1.14M	–	175
2018 Q3	$1.14M	Sell	24,260 -4,839	-17%	-$269K	0.46%	121
2018 Q2	$1.44M	Sell	29,099 -7,236	-20%	-$273K	0.7%	49
2018 Q1	$1.11M	Buy	+36,335	New	+$1.01M	0.58%	86

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EAM Global Investors's MRTX Position: Q4 2019 in Review

EAM Global Investors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2019, closing a stake of 9,186 shares — an estimated $716K sold.

EAM Global Investors first reported a position in MRTX in Q1 2018 and held it in 6 quarters. The position peaked at $2.57M in Q2 2019. 190 funds tracked by Wall St. Rank hold MRTX as of Q4 2019.

EAM Global Investors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
EAM Global Investors sold 9,186 Mirati Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $716K.
EAM Global Investors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2018 and held it in 6 quarters.
EAM Global Investors's Mirati Therapeutics, Inc. Common Stock position peaked at $2.57M in Q2 2019.
190 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2019.

Based on EAM Global Investors's 13F filing for Q4 2019, filed 10 Feb 2020.